论文部分内容阅读
目的探讨对于单用二甲双胍血糖控制不理想的2型糖尿病患者给予艾塞那肽联合口服药降糖方案的有效性及安全性。方法收集60例单用二甲双胍血糖控制不理想的2型糖尿病患者,随机分为艾塞那肽组和甘精组,两组均采用二甲双胍常规治疗,艾塞那肽组加用1 d 1次艾塞那肽,甘精组加用甘精胰岛素1 d 1次,随访52周,观察糖化血红蛋白(HbA1c),空腹血糖(FPG)、餐后2 h血糖(2hPG)等有效性指标,胰岛β细胞功能及体质量指数(BMI),低血糖发生情况。结果艾塞那肽组治疗后空腹血糖和糖化血红蛋白相较于甘精组显著下降(P<0.05),艾塞那肽组△HOMA-13显著高于甘精组(P<0.05),两治疗组体重的改变有着显著差异(P<0.05)。结论艾塞那肽可用于长期的血糖控制,改善胰岛β细胞功能,低血糖风险低,降低体重。
Objective To investigate the efficacy and safety of exenatide combined with oral antidiabetic drugs in patients with type 2 diabetes who are not controlled by metformin. Methods Sixty patients with type 2 diabetes mellitus who were not controlled by metformin alone were randomly divided into exenatide group and Gan Gan group. Both groups were treated with metformin. The exenatide group was treated with 1 d of 1 The results showed that the effective dose of HbA1c, fasting blood glucose (FPG) and 2 hPG (2 hPG) after administration of glargine for 1 d were observed for 1 week and 5 weeks respectively. Function and body mass index (BMI), hypoglycemia. Results Fasting plasma glucose and glycosylated hemoglobin were significantly decreased in the exenatide group compared with those in the control group (P <0.05), △ HOMA-13 in the exenatide group was significantly higher than that of the glycyrrhizin group (P <0.05) Group weight changes have significant differences (P <0.05). Conclusion Exenatide can be used for long-term glycemic control, improve pancreatic β-cell function, low risk of hypoglycemia, reduce body weight.